ARVN vs. RYTM, VERA, RCKT, MRUS, TGTX, CORT, DYN, KROS, SMMT, and EVO
Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Rhythm Pharmaceuticals (RYTM), Vera Therapeutics (VERA), Rocket Pharmaceuticals (RCKT), Merus (MRUS), TG Therapeutics (TGTX), Corcept Therapeutics (CORT), Dyne Therapeutics (DYN), Keros Therapeutics (KROS), Summit Therapeutics (SMMT), and Evotec (EVO). These companies are all part of the "pharmaceutical preparations" industry.
Arvinas (NASDAQ:ARVN) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk.
Rhythm Pharmaceuticals has lower revenue, but higher earnings than Arvinas. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Arvinas has a net margin of -185.09% compared to Rhythm Pharmaceuticals' net margin of -238.50%. Arvinas' return on equity of -70.24% beat Rhythm Pharmaceuticals' return on equity.
Rhythm Pharmaceuticals received 107 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 65.87% of users gave Rhythm Pharmaceuticals an outperform vote while only 64.73% of users gave Arvinas an outperform vote.
Arvinas has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500.
In the previous week, Arvinas had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for Arvinas and 4 mentions for Rhythm Pharmaceuticals. Arvinas' average media sentiment score of 0.68 beat Rhythm Pharmaceuticals' score of 0.29 indicating that Arvinas is being referred to more favorably in the media.
95.2% of Arvinas shares are held by institutional investors. 5.2% of Arvinas shares are held by insiders. Comparatively, 4.7% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Arvinas currently has a consensus price target of $59.73, indicating a potential upside of 84.53%. Rhythm Pharmaceuticals has a consensus price target of $47.20, indicating a potential upside of 23.30%. Given Arvinas' higher probable upside, research analysts plainly believe Arvinas is more favorable than Rhythm Pharmaceuticals.
Summary
Arvinas beats Rhythm Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Arvinas News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
